Other languages Leap Therapeutics, Inc.

Equities

LPTX

US52187K2006

Delayed Nasdaq Other stock markets 01:10:24 2024-05-01 pm EDT			5-day change	1st Jan Change
3.15 ^USD	+1.61%		-4.26%	-24.00%

Apr. 10	Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP	CI
Mar. 19	Baird Adjusts Price Target on Leap Therapeutics to $9 From $11, Maintains Outperform Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Leap Therapeutics Files $200 Million Mixed-Securities Shelf Registration	Mar. 18
Leap Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 18
Leap Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18
Leap Therapeutics, Inc. to Present New Clinical Data from Part A of Defiance Study At the 2024 Asco Gastrointestinal Cancers Symposium	Jan. 16
Leap Therapeutics, Inc. Announces Completion of Enrollment in Randomized Controlled Part C of the Distinguish Study of DKN-01 for the Treatment of Gastric Cancer Patients	Jan. 02
Leap Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Top Premarket Decliners	23-10-16
Top Premarket Decliners	23-10-09
Leap Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Leap Therapeutics, Inc. Announces Initiation of Randomized Controlled Part B of the Defiance Study of DKN-01 in Colorectal Cancer Patients	23-07-12
Leap Therapeutics to Effect 10-for-1 Reverse Stock Split	23-06-20
Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting	23-05-25
Leap Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15
Leap Therapeutics Completes Enrollment of Part A of Phase 2 Study of Potential Colorectal Cancer Combination Therapy	23-04-12
Leap Therapeutics, Inc. Announces Completion of Enrollment in Part A of the Defiance Study of Dkn-01 for the Treatment of Colorectal Cancer Patients	23-04-12
Leap Therapeutics, Inc. Announces the Promotion of Jason Baum to Chief Scientific Officer, Effective April 1, 2023	23-03-24
Leap Therapeutics, Inc. Provides Update on Beigene Option Agreement for DKN-01	23-03-16
Tesla's China sales slow as price-cut boost wanes	23-02-28
Leap Therapeutics Acquires Flame Biosciences in All-Stock Deal	23-01-17
Leap Therapeutics, Inc. Appoints Atricia Martin and Christian Richard to Board of Directors	23-01-17

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Leap Therapeutics, Inc.

Equities

LPTX

US52187K2006

Other languages

Filters